Catalent reaches out to lung cancer patients with research agreement

Catalent ($CTLT) has partnered with the Lung Cancer Alliance to survey patients on how they manage the disease and deal with treatment compliance, an effort to highlight unmet needs and match them with new dosage forms. The partnership centers on the Catalent Applied Drug Delivery Institute, an internal effort to develop new approaches for getting medications to patients safely and effectively. Alongside the Lung Cancer Alliance, Catalent hopes to cull patient insights about barriers to adherence, information that could fuel future R&D. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.